Clinical trial
Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid…
NCT00410566 · Genzyme, a Sanofi Company, Industry · Terminated
Key facts
| NCT number | NCT00410566 |
|---|---|
| Title | Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) |
| Official title | A Phase I, Single-Center, Single Dose, Dose Escalation Study of Recombinant Human Acid Sphingomyelinase (rhASM) in Adults With Acid Sphingomyelinase Deficiency (ASMD) |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Acid Sphingomyelinase Deficiency, Niemann-Pick Disease |
| Intervention type | Drug |
| Interventions | rhASM |
| Enrollment | 11 |
| Start date | Dec 1, 2006 |
| Primary completion | Mar 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Dec 13, 2006 |
| Last update posted | Mar 19, 2015 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: